Breast Cancer CTC Detection Services

Circulating tumor cells (CTCs) are cancer cells that have detached from the primary tumor and entered the bloodstream. CTC detection offers insights into metastatic potential and aids in personalized treatment strategies. Alfa Cytology offers a comprehensive suite of CTC detection services for breast cancer.

Introduction of Breast Cancer CTC

Circulating tumor cells (CTCs) are one of the important target markers in liquid biopsy. CTCs are tumor cells that detach from primary or metastatic tumors and enter the bloodstream during cancer formation or progression. They are often called the "seeds" of tumor recurrence and metastasis. A large number of academic studies have shown that CTCs carry more comprehensive tumor information than other markers and more directly reflect the risk of tumor occurrence. CTCs are present in the blood of many BC patients. If viable CTCs can be isolated from BC patients and genotyped and functionally characterized during treatment, they have the potential to identify the most effective therapies to target the evolving nature of the primary tumor.

Fig.1 Overview of CTC isolation and detection, characterization, and clinical applications. (Lin D, et al., 2021)

Our Services

The sensitivity of CTC detection is better than that of traditional imaging examinations, and the presence of tumor cells can be detected 1-4 years earlier than imaging. Compared with pathological tissue biopsy, CTC detection does not rely on the existence of lesions, is convenient for sampling, and can perform real-time dynamic monitoring. Compared with immunology (tumor markers), CTC detection has high sensitivity and good specificity.

Alfa Cytology provides flexible and rapid CTC detection solutions, including CTC isolation and CTC detection. We have a track record at every stage of the CTC assay development process, helping you save costs and time.

CTC Detection Applications

• Early screening and early diagnosis
  In the ultra-early stage of tumor development, CTCs can be detected in the blood, which is the best period for tumor treatment.
• Efficacy and drug resistance assessment
  Drug effectiveness and the prediction of drug resistance can be determined by analyzing the dynamic counts of CTC and mutations in genes associated with drug resistance.
• Auxiliary staging and prognosis
  Based on the number of CTCs and gene mutations, the prognosis, such as tumor severity and survival time, is determined.
• Tumor dynamic monitoring
  Dynamically monitor the number of CTCs and changes in targeted genes.
• Relapse warning
  CTCs are re-detected, their number increases and gene mutations related to recurrence and metastasis are precursors of tumor recurrence/metastasis.
• Therapeutic development
  Develop personalized therapeutic strategies based on the heterogeneity of CTC.

Alfa Cytology boasts extensive expertise in BC research garnered over many years. We are committed to continuous innovation, perpetually exploring improved solutions for our clientele, and ensuring the delivery of top-notch products and services. If you are interested in learning more about our BC CTC detection services, please don't hesitate to contact us. Our dedicated and knowledgeable staff will promptly get in touch with you.